Dendritic cell-based vaccines for colorectal cancer: Mechanisms, clinical progress and future directions (Review)
6 affiliations
- 1MyGenome Sdn. Bhd., ALPS Global Holding Berhad, 50400 Kuala Lumpur, Malaysia
- 2Celestialab Sdn. Bhd., ALPS Global Holding Berhad, 50400 Kuala Lumpur, Malaysia
- 3Department of Biotechnology, Faculty of Applied Sciences, AIMST University, 08100 Bedong, Kedah, Malaysia
- 4Sunway Medical Centre Sdn. Bhd., 47500 Subang Jaya, Selangor, Malaysia
- 5Department of Biotechnology, Faculty of Intelligent Healthcare Technologies, Nilai University, 71800 Nilai, Negeri Sembilan, Malaysia
- 6Centre for Research Development, University of Cyberjaya, 63000 Cyberjaya, Selangor, Malaysia
Abstract
Dendritic cell (DC)-based vaccines have emerged as a promising immunotherapy against a broad range of cancers. DCs are sentinel antigen-presenting cells that play a pivotal role in cancer immunosurveillance by recognizing tumor antigens via innate immune responses and subsequently stimulating adaptive T-cell-mediated anti-tumor responses. Autologous DC-based vaccines prime the individual's immune system to recognize and destroy tumor cells, aiming to achieve durable anti-tumor immunity and impede tumor relapse. The safety and effectiveness of DC-based vaccines for cancer treatment have been demonstrated in several clinical studies, either as monotherapy (such as Sipuleucel-T) or in combination with other therapies such as chemotherapy and immune checkpoint blockade. The present review provides a comprehensive overview of the current progress and clinical applications of DC-based vaccines for colorectal cancer (CRC). Various subsets of DCs and their biological roles in anti-tumor immunity are explored in detail and the mechanistic insights into DC-based vaccine development are discussed. Additionally, the present review highlighted the outcomes of recent clinical trials of autologous DC-based vaccines for advanced CRC, as well as the challenges and strategies for overcoming them in the development and clinical applications for CRC. Taken together, the potential and limitations of DC-based vaccines for CRC are underscored in the present review to provide an improved understanding and guide future directions in developing efficacious DC-based therapeutic vaccines for CRC.
Related
- PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy
- Myeloid control of dendritic cell priming after mechanical HIFU in colorectal cancer: implications for PD-1/PD-L1 blockade
- From molecular mechanisms to clinical practice: advances in the immune microenvironment and translational therapeutics of colorectal cancer liver metastasis
- Mathematical model for visual cortical development based on molecular mechanisms underlying the generation and elimination of dendritic spines
- Dendritic cells as master regulators of the T-cell axis in sepsis: mechanisms and therapeutic implications
BibTeX
@article{pong2026dendritic,
title = {{Dendritic cell-based vaccines for colorectal cancer: Mechanisms, clinical progress and future directions (Review)}},
author = {Lian Yih Pong and Siti Ayuni Hassanudin and Seng Kong Tham and Ravichandran Manickam and Chee Yin Wong and Keat Seong Poh and Chit Laa Poh},
journal = {International Journal of Oncology},
year = {2026},
month = sep,
doi = {10.3892/ijo.2026.5936},
url = {https://doi.org/10.3892/ijo.2026.5936},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Dendritic cell-based vaccines for colorectal cancer: Mechanisms, clinical progress and future directions (Review)
AU - Lian Yih Pong
AU - Siti Ayuni Hassanudin
AU - Seng Kong Tham
AU - Ravichandran Manickam
AU - Chee Yin Wong
AU - Keat Seong Poh
AU - Chit Laa Poh
PY - 2026
DA - 2026/09/03
JO - International Journal of Oncology
DO - 10.3892/ijo.2026.5936
UR - https://doi.org/10.3892/ijo.2026.5936
AB - Dendritic cell (DC)-based vaccines have emerged as a promising immunotherapy against a broad range of cancers. DCs are sentinel antigen-presenting cells that play a pivotal role in cancer immunosurveillance by recognizing tumor antigens via innate immune responses and subsequently stimulating adaptive T-cell-mediated anti-tumor responses. Autologous DC-based vaccines prime the individual's immune system to recognize and destroy tumor cells, aiming to achieve durable anti-tumor immunity and impede tumor relapse. The safety and effectiveness of DC-based vaccines for cancer treatment have been demonstrated in several clinical studies, either as monotherapy (such as Sipuleucel-T) or in combination with other therapies such as chemotherapy and immune checkpoint blockade. The present review provides a comprehensive overview of the current progress and clinical applications of DC-based vaccines for colorectal cancer (CRC). Various subsets of DCs and their biological roles in anti-tumor immunity are explored in detail and the mechanistic insights into DC-based vaccine development are discussed. Additionally, the present review highlighted the outcomes of recent clinical trials of autologous DC-based vaccines for advanced CRC, as well as the challenges and strategies for overcoming them in the development and clinical applications for CRC. Taken together, the potential and limitations of DC-based vaccines for CRC are underscored in the present review to provide an improved understanding and guide future directions in developing efficacious DC-based therapeutic vaccines for CRC.
SN - 1019-6439
SN - 1791-2423
ER -